Halozyme Therapeutics, Inc.

We have also demonstrated our commitment to returning significant capital to shareholders, repurchasing $333 million of shares in 2Q 2026, at an average price of $69.30.

SEC original ↗Halozyme Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026

Second Quarter Corporate Highlight In May 2026, the Company announced a new share repurchase program to repurchase up to $1.0 billion of its outstanding common stock by December 31, 2028, with an expectation of buying back at least $400 million of shares in 2026.

SEC original ↗Halozyme Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026

During the second quarter of 2026, the Company repurchased 4.8 million shares for $332.8 million at an average price of $69.30 per share under the May 2026 and February 2024 share repurchase programs.

SEC original ↗Halozyme Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026

The February 2024 share repurchase program was completed in June 2026.

SEC original ↗Halozyme Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026

The Company s earnings per share guidance includes new Hypercon and Surf Bio investments of approximately $60 million and does not consider the impact of potential future share repurchases.

SEC original ↗Halozyme Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026

Safe Harbor Statement In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the Company s financial performance (including the Company s expected financial outlook for 2026) and expectations for future growth, profitability, revenue durability, total revenue, royalty revenue, royalty revenue duration, EBITDA, Adjusted EBITDA, and non-GAAP diluted earnings-per-share, and shareholder value and potential future share repurchases.

SEC original ↗Halozyme Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026

Fair Value of Financial Instruments The authoritative guidance for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.

SEC original ↗Halozyme Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, asset-specific commercial and regulatory developments and changes to key personnel or strategy.

SEC original ↗Halozyme Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.

SEC original ↗Halozyme Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The increase was primarily due to an increase in consulting and professional service fees, including litigation costs incurred in connection with patent infringement litigation, the acquisition of Elektrofi and Surf Bio, and an increase in compensation expense.

SEC original ↗Halozyme Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026

The Company calculates Non-GAAP diluted earnings per share excluding share-based compensation expense, amortization of debt discounts, intangible asset amortization, one-time items, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges, transaction costs for business combinations and share-based compensation acceleration expenses, intellectual property litigation costs, inducement expenses related to convertible notes, and certain adjustments to income tax expense.

SEC original ↗Halozyme Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026

The Company calculates adjusted EBITDA excluding one-time items, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges, transaction costs for business combinations and share-based compensation acceleration expenses and intellectual property litigation costs.

SEC original ↗Halozyme Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026

GAAP to Non-GAAP Reconciliations EBITDA (Unaudited) (In thousands) Three Months Ended June 30, 2026 2025 GAAP Net Income $ 229,913 $ 165,160 Adjustments Investment and other income, net (2,581) (6,891) Interest expense 5,588 4,394 Income tax expense 54,989 39,778 Depreciation and amortization 33,967 20,502 EBITDA 321,876 222,943 Adjustments Intellectual property litigation costs (1) 6,936 2,561 Adjusted EBITDA $ 328,812 $ 225,504 (1) Adjustment relates to litigation costs incurred by Halozyme in connection with Halozyme s patent infringement litigation against Merck Sharp Dohme LLC ( Merck ).

SEC original ↗Halozyme Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026

(1) Adjustment relates to litigation costs incurred by Halozyme in connection with Halozyme s patent infringement litigation against Merck.

SEC original ↗Halozyme Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026

These forward-looking statements are typically, but not always, identified through use of the words expect, believe, enable, may, will, could, intends, estimate, anticipate, plan, predict, probable, potential, preliminary, possible, should, continue, and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.

SEC original ↗Halozyme Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2026